Dolutegravir knocks down HIV faster than bictegravir
Experts publish recommendations on managing low-level but detectable HIV
Worse HIV control at diagnosis doesn't mean worse lymphoma outcomes
Low-level but detectable HIV raises the risk of treatment failure, but not long-term harm
Positive interactions with healthcare workers improve HIV care retention in Malawi and Zambia
Most people on dolutegravir resuppress viral load after a detectable result
Retention in HIV care has declined since 'Treat All' guidelines introduced
Persistent low-level viraemia raises the risk of serious non-AIDS events
Giving a figure for HIV viral load below 200 is a “harmful medical practice”
